Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
ADICON Holdings Limited ( (HK:9860) ) just unveiled an announcement.
ADICON Holdings Limited announced its annual results for 2024, revealing a decrease in revenue and profit compared to 2023. Despite economic challenges, the company reported growth in its base testing, esoteric testing, and co-construction business segments. ADICON has finalized a five-year strategic plan to enhance its esoteric business, focusing on innovation and technology integration. The company is investing in digital transformation, deploying AI and a new Laboratory Information Management System to improve efficiency and diagnostic capabilities.
More about ADICON Holdings Limited
ADICON Holdings Limited operates in the in-vitro clinical laboratory (ICL) industry, focusing on diagnostic services. The company is known for its base and esoteric testing services, co-construction business, and its commitment to innovation in areas such as hematology, oncology, neuroimmunology, and chronic diseases.
YTD Price Performance: -17.52%
Average Trading Volume: 1,245,359
Technical Sentiment Signal: Buy
Current Market Cap: HK$5.41B
For detailed information about 9860 stock, go to TipRanks’ Stock Analysis page.